Efficacy of autologous bone marrow buffy coat grafting combined with core decompression in patients with avascular necrosis of femoral head: a prospective, double-blinded, randomized, controlled study by Ma, Yuanchen et al.
The University of Notre Dame Australia 
ResearchOnline@ND 
Health Sciences Papers and Journal Articles School of Health Sciences 
2014 
Efficacy of autologous bone marrow buffy coat grafting combined with 
core decompression in patients with avascular necrosis of femoral head: a 






See next page for additional authors 
Follow this and additional works at: https://researchonline.nd.edu.au/health_article 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
 
This article was originally published as: 
Ma, Y., Wang, T., Liao, J., Gu, H., Lin, X., Jiang, Q., Bulsara, M., Zheng, M., & Zheng, Q. (2014). Efficacy of autologous bone marrow 
buffy coat grafting combined with core decompression in patients with avascular necrosis of femoral head: a prospective, double-
blinded, randomized, controlled study. Stem Cell Research and Therapy, 5 (115). 
http://doi.org/10.1186/scrt505 
This article is posted on ResearchOnline@ND at 
https://researchonline.nd.edu.au/health_article/130. For more 
information, please contact researchonline@nd.edu.au. 
Authors 
Yuanchen Ma, Tao Wang, Junxing Liao, Honglin Gu, Xinpeng Lin, Qing Jiang, Max Bulsara, Minghao Zheng, 
and Qiujian Zheng 
This article is available at ResearchOnline@ND: https://researchonline.nd.edu.au/health_article/130 
RESEARCH Open Access
Efficacy of autologous bone marrow buffy coat
grafting combined with core decompression in
patients with avascular necrosis of femoral head:
a prospective, double-blinded, randomized,
controlled study
Yuanchen Ma1, Tao Wang1,2, Junxing Liao1, Honglin Gu1, Xinpeng Lin1, Qing Jiang3, Max K Bulsara4,
Minghao Zheng2* and Qiujian Zheng1*
Abstract
Introduction: Avascular necrosis of femoral head (ANFH) is a progressive disease that often leads to hip joint
dysfunction and even disability in young patients. Although the standard treatment, which is core decompression,
has the advantage of minimal invasion, the efficacy is variable. Recent studies have shown that implantation of
bone marrow containing osteogenic precursors into necrotic lesion of ANFH may be promising for the treatment
of ANFH.
Methods: A prospective, double-blinded, randomized controlled trial was conducted to examine the effect of
bone-marrow buffy coat (BBC) grafting combined with core decompression for the treatment of ANFH. Forty-five
patients (53 hips) with Ficat stage I to III ANFH were recruited. The hips were allocated to the control group (core
decompression + autologous bone graft) or treatment group (core decompression + autologous bone graft with
BBC). Both patients and assessors were blinded to the treatment options. The clinical symptoms and disease
progression were assessed as the primary and secondary outcomes.
Results: At the final follow-up (24 months), there was a significant relief in pain (P <0.05) and clinical joint symptoms
as measured by the Lequesne index (P <0.05) and Western Ontario and McMaster Universities Arthritis Index (P <0.05)
in the treatment group. In addition, 33.3% of the hips in the control group have deteriorated to the next stage after
24 months post-procedure, whereas only 8% in the treatment group had further deterioration (P <0.05). More
importantly, the non-progression rates for stage I/II hips were 100% in the treatment group and 66.7% in the
control group.
Conclusion: Implantation of the autologous BBC grafting combined with core decompression is effective to prevent
further progression for the early stages of ANFH.
Trial registration: ClinicalTrials.gov identifier NCT01613612. Registered 13 December 2011.
* Correspondence: Minghao.zheng@uwa.edu.au; zqj650@126.com
2Centre for Orthopaedic Translational Research, School of Surgery, The
University of Western Australia, M Block, QE2 Medical Centre, Monash Ave.,
Nedlands, WA 6009, Australia
1Division of Orthopaedic Surgery, Department of Surgery, Guangdong
General Hospital, Guangdong Academy of Medical Sciences, 106
Zhongshaner Rd., Guangzhou, Guangdong, 510080, P.R. China
Full list of author information is available at the end of the article
© 2014 Ma et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Ma et al. Stem Cell Research & Therapy 2014, 5:115
http://stemcellres.com/content/5/5/115
Introduction
Avascular necrosis of femoral head (ANFH) is a progressive
disease that often leads to hip joint dysfunction and thus
disability in young patients. It is often initiated by insuffi-
cient blood supply to the femoral head, leading to increased
intraosseous pressure and consequently causing subchon-
dral plate collapse and osteoarthritis [1]. Total hip replace-
ment is the common option for terminal ANFH; however,
owing to poor prosthetic durability, it is not preferable for
young patients [1]. Early intervention prior to subchondral
bone collapse would thus be critical to preserve joint struc-
ture and function, which may postpone the need of total
hip replacement in these patients. Conservative techniques,
such as core decompression and avascular or vascularized
bone grafting, have been used for the treatment of early-
stage ANFH and shown good to moderate results [2-4].
Core decompression is the most common procedure as it
is of minimal invasion. However, the efficacy of this tech-
nique has been variable. The clinical failure rate of this
technique reached 30% in early-stage (Ficat stage I/II) pa-
tients [3,5]. Vascularized or non-vascularized bone-grafting
provides a better subchondral support and has been proven
to be successful in reserving hip joint function and post-
poning the time for hip joint replacement [6]. However, the
technique is more invasive and has complications such as
donor site morbidity and nerve palsy. Thus, it is of import-
ance to seek minimal invasive approaches with better clin-
ical outcomes for the treatment of ANFH.
Accumulating evidence indicated that ANFH is associ-
ated with a decreased pool of osteoprogenitor cells in the
bone marrow of femoral head [7-10]. Previous studies have
shown that implantation of bone marrow containing osteo-
genic precursors into necrotic lesion of ANFH may be
beneficial. Indeed, three out of four ANFH patients who
received skeletal stem cell and milled-allograft bone ther-
apy remained asymptomatic at 22 to 44 months’ follow-up
[11], indicating that the efficacy of using skeletal bone mar-
row cells is promising for the treatment of ANFH. How-
ever, these studies are only at the proof-of-concept stage
and require further clinical investigation [12,13]. In
addition, the use of allograft bone may have potential side
effects such as virus infection for the treated patients.
Therefore, to minimize potential side effects as well as
improve clinical outcomes, this study aims to combine
minimal invasive core decompression technique, autolo-
gous bone graft from the affected femoral head, and
bone-marrow buffy coat (BBC) implantation to investi-
gate the clinical efficacy of this strategy on patients with
Ficat stage I to III ANFH.
Materials and methods
Patients
Eligible patients were recruited from people adminis-
trated in the Department of Orthopedic Surgery (name
of institution blinded) from June 2009 to Octorber 2010.
All participants had plain radiograph of the hips at the
anteroposterior and frog-leg lateral positions and mag-
netic resonance imaging [14]. Diagnosis of ANFH was
made on the basis of clinical history and the presence of
lesion in plain radiograph. Inclusion criteria were age
between 18 to 55 years; notable pain in the hip; and nor-
mal, minor, or mixed osteopenia or the presence of cres-
cent sign in plain radiograph. Patients with confirmed
diagnosis of osteonecrosis in another joint and one or
more associated risk factors were also recruited in the
study. Exclusion criteria included the following: age of
less than 18 or older than 55, end stage of ANFH with
evidence of secondary degenerative changes, pregnancy,
history of femoral head/neck fracture, tumor, or any
other pathology; having previously received surgical/
invasive intervention on hip, including core decompres-
sion, bone graft implantation, titanium implantation, and
osteotomy; having received steroid treatment in the last
6 months; having systemic disorders such as diabetes,
rheumatoid arthritis, and hepatitis; and incapability to
understand or follow instructions. The study protocol was
approved by the Guangdong General Hospital Human
Ethical Committee, and informed consent was obtained
from the participants. The trial protocol was submitted to
ClinicalTrials.gov, and the trial registration number is
NCT01613612.
Study design
The study is a randomized, participant- and outcome
assessor-blinded, controlled trial. After being determined
eligible for the study, the participants were provided
with informed consent, had a baseline assessment, and
were subjected to randomization. A computer using block
randomization of 10 hips was used to generate a
randomization schedule. The hips were thus randomly al-
located to receive core decompression + autologous bone
graft or core decompression + autologous bone graft with
BBC. All patients were blinded to treatment options. The
surgeon performing the procedure was blinded to the pa-
tients’ clinical presentation but informed of the procedures
of core decompression with or without BBC implantation.
Patients with bilateral ANFH may receive different treat-
ments on both hips at the same day. Outcome assessors
were blinded to group assignment.
Power calculation
The power of both groups was determined by using the
results from previous publication [15]. At least 20 pa-
tients per group are necessary to measure the difference
by using the Wilcoxon-Mann-Whitney test with a bilat-
eral alpha of 0.017 and a power of 80%. To compensate
for the patients lost to follow-up, we included a mini-
mum of 26 patients in each group.
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Core decompression
The patients were positioned supine on the operation
table and anesthetized by continuous epidural anesthesia.
For core decompression of the femoral head, a 1.5-cm in-
cision was made over the skin and the fascia on the lateral
aspect the thigh at the level of the greater trochanter. A
Kirschner wire (k-wire) was driven into the mid-line of the
trochanter by a cannulated drill under C-arm x-ray guid-
ance, pointing toward the necrotic area. The tip of the
k-wire was placed at the subchondral bone region with
a distance of 2 to 3 mm from the articular cartilage
(Figure 1A). A 10-mm diameter trephine was placed
through the k-wire and driven toward the necrotic site. A
cylinder of bone from the femoral neck and head was ob-
tained and used for bone marrow grafting (Figure 1B).
The necrotic tissue in the femoral head was removed by
using the bone curette.
Bone marrow aspiration and bone-marrow buffy coat
implantation
After the patient received continuous epidural anesthesia,
the pelvic bone was punctured from the superior posterior
iliac spine with the bone marrow aspiration needle
(Biomid; Gallini Medical Devices, Mantova, Italy). The
needle was rotated back and forth to achieve penetration
through the cortical bone. A 50-mL heparinized syringe
was connected to the bone marrow aspiration needle and
used to harvest the bone marrow. The patients who re-
ceived single core decompression underwent the same
procedure except that no bone marrow was aspirated from
the iliac crest. To obtain the BBC with enriched nucleated
cells, bone marrow was centrifuged at 1500 revolutions
per minute for 10 minutes in a bench-top centrifuge with
a sterilized chamber. After centrifuge, the bone marrow
was separated into three phases. The blood serum from
the superficial layer was removed, and the BBC from the
interface containing enriched bone marrow cells was col-
lected by a sterilized transfer pippet and carefully loaded
onto the porous cylindrical bone drop by drop. A total of
1 mL of BBC was isolated from the suspension, and 10 μL
of BBC was kept for cell counting after the surgery. The
average bone marrow cells loaded to the cylindrical bone
were approximately 3 × 109 nucleated cells. To allow the
cells to anchor on the bone surface, the BBC was seeded
on the cylindrical bone for 2 minutes before implantation.
The bone graft was inserted into the necrotic region
through the trephine. C-arm x-ray was used to ensure that
the bone graft was placed into the necrotic site. For
the patients who received single core decompression, the
cylindrical bone was inserted into the necrotic region
without the buffy coat. After surgery, the patients were
instructed to remain non-weight-bearing for 4 weeks.
Surgical complications, such as bone marrow harvest site
infection, surgical site infection, and breeding, were moni-
tored after operation.
Outcome measurement
The blinded assessor evaluated all participants at base-
line and at 3 and 24 months postoperatively. Baseline
demographic information, including age, sex, etiological
factors, presurgical Ficat stage of ANFH, and location of
defect, was collected. Ficat stage of ANFH and the loca-
tion of necrotic lesion in each hip were determined by
plain x-ray radiograph and magnetic resonance imaging.
The primary outcomes were the average pain on move-
ment and function of hip. The pain was assessed by vis-
ual analogue scale (VAS). The function of hip was
evaluated by using Lequesne algofunctional index and
Western Ontario and McMaster Universities Arthritis
Index (WOMAC) osteoarthritis scoring [15].
Secondary outcome was the improvement of disease
progression determined by the stage of osteonecrosis and
the status of subchondral bone collapse at the time of the
final follow-up. The patients were followed for up to
24 months. Anteroposterior and frog-leg lateral radio-
graphs were taken at the time of each clinical assessment.
Figure 1 Image of operation procedure. (A) Radiography of the femoral head at the time of the operation. The Kirschner wire and 10-mm
diameter trephine were driven into the mid-line of the trochanter by a cannulated drill under C-arm x-ray guidance toward the necrotic area.
(B) A 3.5-cm long cylindrical bone was taken from the trochanter through the trephine and used for bone graft to enriched bone
marrow incorporation.
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Magnetic resonance images of the affected hip were made
at baseline and at the last follow-up. Radiographic pro-
gression of the ANFH was determined according to the
Ficat and alert classification system. All radiographs were
analyzed by the same blinded assessor who did not partici-
pate in the treatment.
Statistical analysis
Variables are described as the mean and the standard
deviation of the mean. The statistical significance of
demographic structure, pre-operative evaluation, and
clinical outcomes between two groups were determined
by the Wilcoxon-Mann-Whitney test. The paired t test
was used to compare the clinical assessment before and
after operation. To account for multiple joints in the
same patient, a linear mixed model was used to test for
within-group differences. The significance for all tests
was defined as a P value of less than 0.05.
Results
General information and patient flow chart
Ninety-four hips (77 patients) were screened for eligibil-
ity, and 41 hips (34 patients) were excluded. Finally, 45
patients with 53 hips were recruited and randomly
assigned into two groups. Four patients with four hips
were lost to follow-up at 3 months. Forty-nine hips (for
43 patients) have completed the clinical trial and were
included in the final analysis (Figure 2). The demo-
graphic data and baseline characteristic of the hips are
listed in Table 1. At the basal level, there was no signifi-
cant difference of the stages of ANFH, etiological factors
of the disease, the age of patients, and the clinical symp-
toms between two groups. Seven patients were bilat-
erally affected by ANFH. Eight hips had Ficat stage I
osteonecrosis, 32 hips had Ficat stage II osteonecrosis,
and 10 hips had stage III osteonecrosis. Twenty-six pa-
tients (29 hips) had a history of corticosteroid therapy,
and seven patients (eight hips) had alcohol-induced
ANFH. Twelve patients were idiopathic. The average age
of the patients was 35 ± 9.8 years. There were 33 antero-
superior lesions at the weight-bearing sites and 16
lesions at the non-weight-bearing sites when the patients
stood upright. All of the patients had reported notable
pain in one or both hips. The hips in the control group
were treated with single core decompression and im-
plantation of autologous bone graft, and the treatment
group was processed to core decompression and im-
plantation of autologous bone grafted with enriched
autologous bone-marrow nucleated cells. Twenty-two
patients had bilateral ANFH. Among those, 10 patients
(20 hips) received core decompression with/without
BBC on both hips, and 12 patients received total hip re-
placement on one side of the hip for the treatment of
end-stage osteonecrosis and core decompression with/
without BBC on the other side for early osteonecrosis.
Overall, 49 hips were available for final analysis. No
complication was observed in the patients during or
after the core decompression with/without BBC grafting.
Figure 2 Flow chart of patient enrollment and randomization.
Table 1 Demographic data of the participants and
baseline characteristics of the hips
Control BBC implantation P value
Number of patients 18 21





55+ 1 0 0.61
Sex
Male 13 15





Number of joints 24 25
Ficat I 4 3
Ficat II 15 17




*P =0.99. BBC, bone-marrow buffy coat.
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Primary outcomes of clinical symptom improvement
In the control group with core decompression only,
there is a slight increase of VAS from 35.21 ± 3.41 mm
at the basal level to 38.75 ± 3.27 mm at 3 months after
operation, but this decreased to 26.46 ± 2.60 mm at
24 months’ follow-up (P =0.007) (Figure 3A). In con-
trast, in the group of patients with core decompression
combined with BBC, the level of pain measured by VAS
was significantly decreased at 24 months after surgery.
The mean value of VAS was significantly decreased from
35.58 ± 4.21 mm at the basal level to 24.62 ± 3.50 mm at
3 months (P <0.0.001) and 16.92 ± 3.66 mm (P <0.001)
at the final follow-up (Figure 3A). Patients treated with
core decompression combined with BBC also have a
significant improvement in the joint symptoms, as evi-
denced by the Lequesne index and WOMAC score.
The mean of Lequesne index decreased from 9.58 ± 0.99
at the basal level to 5.83 ± 0.93 (P <0.001) after 24 months
in the BBC grafted group (Figure 3B). In addition, the aver-
age scores of WOMAC were 27.77 ± 4.23 at baseline and
14.81 ± 2.99 (P <0.001) at the last follow-up (Figure 3C).
Secondary outcome of disease progression
At the 3 months’ follow-up of core decompression group,
two hips were classified from Ficat stage I to stage II,
and six hips in Ficat stage II developed into stage III/IV
(Figure 4B). At the last follow-up, four patients had under-
gone total hip replacement surgery in the control group.
The progress rates in the control group were 16.6% (4/24)
at 3 months’ follow-up and 33.3% (8/24) at 2 years
(Figure 4A). In the group that received core decompres-
sion + BBC implantation, only two hips had noted aggra-
vation after treatment (Figure 4B). Both of them had
progressed from Ficat stage III to stage IV and were sub-
jected to total hip replacement. The progress rate in the
treatment group was 8% (2/25) at 3 months’ and 2 years’
follow-up (Figure 4A). Most importantly, the progression
rates for early-stage (I/II) hips were 0% in the treatment
group and 33.3% in the control group.
Discussion
This randomized, prospective, double-blinded cohort
controlled study was designed to test the clinical out-
come of BBC grafting combined with miminal invasive
core decompression on patients with ANFH. Both pain
relief and hip joint functional improvement were docu-
mented following the combined BBC implantation and
core decompression after 3 months and 2 years. This
combined strategy also reduced the disease progression
of ANFH compared with core decompression without
BBC implantation, especially when treated at the early
stage (Ficat stage I/II). This strategy is proven to be safe,
minimally invasive, and effective for the treatment of
ANFH, especially at an early stage.
In this study, we conducted a 24 months’ follow-up on
the patients, as collapse of femoral head is usually found
in this period [15,16]. Several classification systems have
been introduced to determine the stage of the disease, in-
cluding those of Ficat and Arlet, University of Pennsylva-
nia, Association Research Circulation Osseous, and the
Japanese Orthopaedic Association [16]. To be comparable
to similar studies, we adopted the most widely used classi-
fication system: Ficat and Arlet [15]. In this study, patients
with Ficat stage I to III ANFH were enrolled for treatment.
No femoral head with early osteonecrosis (Ficat I/II) was
found to have further deterioration at 24 months’ follow-
up after combined core decompression and BBC implant-
ation, whereas two out of five femoral heads with Ficat III
ANFH progressed to collapse. There is a significant differ-
ence in relief of pain and improvement of hip joint func-
tion following the combined BBC implantation and core
decompression after 3 months and 2 years. Although the
number of Ficat III patients was limited in this study, it is
suggested that the stage of ANFH might determine the
Figure 3 A comparison between the control group and bone-marrow buffy coat (BBC) group of the visual analogue scale (A), the
Lequesne index (B) and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score (C) at the pre-operation,
3 months post-operation, and 24 months post-operation. The results were present as mean ± standard error of the mean. Asterisk (*)
indicated a significant difference compared with the baseline; pound sign (#) indicated a significant difference compared with the control group.
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success rate of bone marrow implantation. Early diagnosis
and treatment might improve the clinical outcome using
this combined approach.
ANFH is one of the devastating causes of disability in
young patients. Early treatment of the disease should aim
to prevent femoral head collapse and rescue hip joint
function. Several treatment strategies have been tested to
save the femoral head prior to collapse, including pharma-
cotherapies, physiotherapies, core decompression, vascu-
larized or non-vascularized bone-grafting, and osteotomy
[2,4,17-19]. As mentioned, single core decompression is
the most common procedure applied because it is minim-
ally invasive. In addition, core decompression has been
proven to be partially effective in preserving femoral head
collapse by reducing the intraosseous pressure and regen-
erating circulation that are beneficial to the disease. How-
ever, the efficacy of this technique has been variable.
Particularly, single core decompression using 8 to 10 mm
trephine might further deprive the subchondral support
and accelerate femoral head subsidence. Small-diameter
core decompression was developed to reduce cartilage
damage and subchondral fracture [1]. However, the clin-
ical failure rate of this technique still reached 30% in Ficat
stage I/II patients [3,5]. Thus, core decompression is min-
imally invasive but still has a high failure rate without
bone grafting.
To reduce the failure rate, we modified the technique
by using the autologous bone graft obtained through the
trephine. The implantation of these bone tissues could
enhance subchondral support, thus restraining further
collapse. This has been shown by our computed tomog-
raphy scanning of the femoral head that demonstrated
the necrotic site was filled with a substance of similar
density to bone after surgery, which was sustained for at
least 6 months. This modified technique is different
from other grafting techniques, which normally use vas-
cularized or non-vascularized bone-grafting to provide a
better subchondral support. However, the harvest of
bone grafting from either fibula bone or iliac bone is
very invasive and has complications such as donor site
Figure 4 Long-term follow-up of disease progression. (A) Rate of progression for the control group and bone-marrow buffy coat (BBC) group
of different stage avascular necrosis of femoral head (ANFH) at 3 months’ and 24 months’ follow-up. (B) Cumulative percentage of different Ficat
stages of hip in the control and BBC group at pre-operation, 3 months post-operation, and 24 months post-operation.
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morbidity or nerve injury. The use of autologous bone
from femoral head can avoid these side effects and pro-
vide some mechanical support in the femoral head.
In addition to mechanical support, the autologous
bone graft is also an ideal biomaterial for loading cells to
enhance bone regeneration in the present study. The
bone graft provides an ultimate micro-environment for
cell anchoring and attachment, retaining the maximal
number of implanted cells. Moreover, the healthy bone
graft would support the proliferation and differentiation
of osteoprogenitor cells, facilitating bone formation. In-
deed, accumulating evidence suggested that impaired
bone formation of ANFH was caused by the reduction
of focal mesenchymal stem cell pool and the number
of osteoprogenitor cells [7-9]. Enriched bone marrow
contains pluripotent stem/progenitors, which may con-
tribute to both bone formation and blood vessel recon-
struction in bone defect [15,20,21]. A limited number of
randomized controlled studies of autologous bone mar-
row grafting for early ANFH have been carried out
[15,22-25]. The result of a prospective study of autolo-
gous bone marrow grafting on 189 femoral heads re-
vealed that the treatment was efficient for preventing the
progression of ANFH [23]. A comparison study by
Gangji and colleagues [15] showed that the patients who
received bone marrow mononuclear cell implantation
had a significant reduction in pain and joint symptoms
compared with the control group. The progression rate
decreased from 62.5% in the control to 10% in the bone
marrow graft group at 2 years’ follow-up [15]. Five years’
follow-up of the study further confirmed that the tech-
nique was effective for the treatment of stage I and stage
II osteonecrosis [26]. Furthermore, besides containing
mesenchymal stem cells, the human BBC contains vari-
ous types of progenitor cells and growth factors, includ-
ing endothelia progenitor cells, vascular endothelial
growth factor, transforming growth factor-beta, and
basic fibroblast growth factor [27]. The endothelia pro-
genitor cells play an essential role in angiogenesis and
could correct the ischemia situation in osteonecrotic le-
sion. The growth factors might further enhance bone re-
generation. In agreement with the current literature, our
study has shown that core decompression combined
with the autologous bone marrow grafting in the nec-
rotic site of femoral head might be effective for the treat-
ment of ANFH, particularly at the precollapse stages
(Ficat stage I/II).
Thus, our strategy integrated the advantages of core de-
compression, autologous bone graft, and BBC implantation
to conduct this prospective double-blinded controlled clin-
ical trial. This strategy is relatively feasible and favored by
the clinicians. The BBC containing enriched population of
mononuclear cells and cytokines could be directly loaded
onto the autologous bone graft from femoral head, which
can be implanted back immediately without in vitro cell
expansion [28]. The clinicians could harvest and trans-
plant the cells during the same surgical procedure and
bypass the time-consuming process of cell proliferation
and differentiation. The efficacy of the technique is
supported by our primary outcome of pain relief and
secondary outcome of hip joint function improvement.
In addition, this is supported by the new bone formation
in the femoral head, indicated by increased focal bone
density.
There are some limitations of the study. The etiology
and Ficat stages of ANFH were diverse in the partici-
pants, and the subclass patient number was limited. The
number in each subclass was not able to reach efficient
calculation power, and thus we did not perform statis-
tical analysis on each subclass, and so further studies
with a larger sample size and a longer follow-up period
will be required. Although it has been suggested that the
treatment outcome of osteonecrosis may be influenced
by the cause and the stage, the numbers of each subclass
between two groups was comparable. Thus, it is sug-
gested that the implantation of BBC does have beneficial
effect for the treatment of ANFH at an early stage, re-
gardless the diverse etiological factors. However, further
studies with better control on etiological factors and
stage of disease will be required. Moreover, to monitor
whether the implanted cells remained at the site of im-
plantation, cell labeling will have be adapted; however,
this proposal was not approved by the ethics committee.
Lastly, in this study, patients were recruited according to
clear enrolment criteria; however, we did not exclude
the patients with bilateral ANFH. Therefore, there might
be a potential contralateral effect associated with the cell
treatment.
In conclusion, this study demonstrated that the com-
bined approach of core decompression and BBC graft-
ing could be used to prevent femoral head collapse in
early-stage ANFH at 2 years’ follow-up. The result
highlighted the positive effect of enriched bone marrow
cells in the regeneration of focal bone necrosis. Further
investigations need to be carried out to seek treatment
strategies for pre-osteoarthritis ANFH after subchon-
dral bone collapse.
Conclusion
The present study showed that the implantation of the
autologous BBC grafting combined with core decom-
pression is effective to prevent further progression for
the early stages of ANFH.
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